Clinical and economic burden of head and neck cancer : a nationwide retrospective cohort study from France

2019

Article référencé dans le Web of Science WOS:000476513600001

Schernberg A., Sagaon Teyssier Luis, Schwarzinger M., Baillot S., Bec M., Benmahammed L., Even C., Geoffrois L., Huguet F., Le Vu B., Levy-Bachelot L., Luchini S., Pointreau Y., Robert C., Temam S., Epicorl Study Group

Clinicoeconomics and Outcomes Research, 2019, 11, p. 441-451 ISSN 1178-6981

Objectives: To evaluate the clinical and economic burden of head and neck squamous cell carcinoma (HNSCC) in France. Methods: All 53,255 incident adult patients discharged with a first diagnosis of HNSCC in 2010-2012 were identified from the 2008-2013 French National Hospital Discharge (PMSI) database. We conducted a retrospective longitudinal analysis of prognosis and direct costs attributable to HNSCC. Results: Direct medical costs attributable to HNSCC care amounted to 665 million euros in 2012 in France. The majority (62%) of incident patients were 64 years old or less at HNSCC diagnosis and incurred 1.3-fold higher mean direct costs as compared to elderly patients (41,909 vs 32,221 euros over 3 years, respectively; p<0.001). HNSCC stage at initial treatment was the major driver of mean (SD) direct costs over 3 years (p<0.001): 19,819 (23,150) euros in 31% patients diagnosed at early stage; 46,791 (34,841) euros in 60% patients diagnosed at locally advanced stage; and 43,377 (33,953) euros in 9% patients diagnosed with distant metastasis. About half patients died over 3 years at a median (IQR) age of 63 (56-75) years resulting in 10.9 years-of-life lost on average per incident patient. Conclusion: The present study suggests that the clinical and economic burden of HNSCC is substantial in France.

Santé : aspects socioculturels, économiques et politiques [056]

FRANCE

Fonds IRD [F B010076249]

fdi:010076249